NCT05251090View on ClinicalTrials.gov

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

November 15, 2021

Study Completion Date

May 9, 2022

Conditions
Hemophilia A
Interventions
DRUG

ADVATE

50 international units (IU)/kg, a single dose.

DRUG

FRSW107

50 IU/kg, a single dose.

Trial Locations (6)

100045

Beijing Children's Hospital,Capital Medical University, Beijing

266000

The Affiliated Hospital of Qingdao University, Qingdao

430000

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan

510515

Nanfang Hospital of Southern Medical University, Guangzhou

518000

Shenzhen Children's Hospita, Shenzhen

610000

Chengdu Women's and Children's Central Hospital, Chengdu

All Listed Sponsors
lead

Jiangsu Gensciences lnc.

INDUSTRY